MarketCap
Facebook
X
Telegram
Curis Market Cap | CRIS
As of September 24, 2026 Curis has a market cap of $ 12.5 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Curis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.48 M | 13.2 M | 55.6 M | 2.76 M | 292 M | 570 M | 53.8 M | 38.1 M | 99.9 M | 359 M | 202 M | 158 M | 243 M | 242 M | 363 M | 22.9 B | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 B | 2.76 M | 1.6 B |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
ADC Therapeutics SA
ADCT
|
139 M | $ 1.31 | 6.5 % | $ 166 M |  Schweiz |
 |
ADMA Biologics
ADMA
|
3.78 B | $ 9.7 | 3.21 % | $ 2.31 B |  USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
2.48 B | $ 27.89 | 0.3 % | $ 4.23 B | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
217 M | $ 13.3 | 1.06 % | $ 364 M |  Israel |
 |
AbbVie
ABBV
|
400 B | $ 265.08 | 0.02 % | $ 469 B | USA |
 |
Axsome Therapeutics
AXSM
|
8.67 B | $ 193.45 | 0.24 % | $ 9.62 B | USA |
 |
Aytu BioScience
AYTU
|
27.5 M | $ 2.28 | 2.24 % | $ 28.1 M | USA |
 |
Adagene
ADAG
|
224 M | $ 2.97 | 0.62 % | $ 175 M |  China |
 |
Abeona Therapeutics
ABEO
|
252 M | $ 5.53 | 2.65 % | $ 293 M | USA |
 |
Adial Pharmaceuticals
ADIL
|
1.31 M | $ 4.04 | 0.24 % | $ 2.7 M | USA |
 |
Evelo Biosciences
EVLO
|
27 M | - | -14.46 % | $ 27.9 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
11.7 B | $ 62.21 | 0.06 % | $ 11.9 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
847 M | $ 4.85 | 0.2 % | $ 929 M |  Canada |
 |
Can-Fite BioPharma Ltd.
CANF
|
4.81 M | $ 2.16 | 0.45 % | $ 3.56 M | Israel |
 |
Achieve Life Sciences
ACHV
|
126 M | $ 7.83 | 0.87 % | $ 341 M | USA |
 |
Catalyst Biosciences
CBIO
|
999 M | $ 14.19 | 1.17 % | $ 1.27 B | USA |
 |
Amryt Pharma plc
AMYT
|
2.55 B | - | - | $ 621 M |  Britain |
 |
C4 Therapeutics
CCCC
|
234 M | $ 3.08 | 0.3 % | $ 255 M | USA |
 |
Codexis
CDXS
|
111 M | $ 1.38 | 0.72 % | $ 120 M | USA |
 |
Allakos
ALLK
|
114 M | - | - | $ 28.6 M | USA |
 |
Cerus Corporation
CERS
|
496 M | $ 2.6 | 4.3 % | $ 496 M | USA |
 |
Coherus BioSciences
CHRS
|
226 M | $ 1.26 | 1.48 % | $ 148 M | USA |
 |
Celldex Therapeutics
CLDX
|
2.04 B | $ 31.12 | 0.28 % | $ 2.07 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
4.64 M | $ 4.04 | 4.94 % | $ 49.3 M | Israel |
 |
AbCellera Biologics
ABCL
|
962 M | $ 12.31 | 0.12 % | $ 3.68 B | Canada |
 |
Aclaris Therapeutics
ACRS
|
385 M | $ 5.26 | 2.69 % | $ 645 M | USA |
 |
Фармсинтез
LIFE
|
2 B | - | - | - |  Russia |
 |
Clovis Oncology
CLVS
|
262 M | - | -7.23 % | $ 13 M | USA |
 |
Cocrystal Pharma
COCP
|
11.4 M | $ 1.19 | 1.26 % | $ 13.4 M | USA |
 |
Collegium Pharmaceutical
COLL
|
1.4 B | $ 22.45 | 1.05 % | $ 711 M | USA |
 |
Corcept Therapeutics Incorporated
CORT
|
3.75 B | $ 112.94 | 3.29 % | $ 11.7 B | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
4.11 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
127 M | $ 7.74 | 0.19 % | $ 103 M | USA |
 |
Cardiff Oncology
CRDF
|
116 M | $ 1.31 | 0.74 % | $ 87.6 M | USA |
 |
CorMedix
CRMD
|
456 K | $ 7.69 | 0.06 % | $ 554 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
4.39 B | $ 55.76 | 1.2 % | $ 5.01 B | Schweiz |
 |
Corvus Pharmaceuticals
CRVS
|
318 M | $ 12.54 | 8.21 % | $ 990 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
104 M | - | - | $ 401 M | USA |
 |
Cue Biopharma
CUE
|
29.4 M | $ 31.71 | 2.62 % | $ 3 B | USA |
 |
CEL-SCI Corporation
CVM
|
19.9 M | $ 1.68 | 0.59 % | $ 13.5 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
7.55 M | $ 65.81 | 0.04 % | $ 7.9 M | USA |
 |
Axon Enterprise
AXON
|
30.6 B | $ 450.61 | 1.61 % | $ 35.2 B | USA |
 |
Brickell Biotech
BBI
|
11.4 M | - | -5.38 % | $ 6.06 M | USA |
 |
DiaMedica Therapeutics
DMAC
|
312 M | $ 7.56 | 7.16 % | $ 355 M | USA |
 |
Denali Therapeutics
DNLI
|
2.41 B | $ 20.46 | 5.52 % | $ 3.53 B | USA |
 |
Precision BioSciences
DTIL
|
64.6 M | $ 6.36 | 10.62 % | $ 81.6 M | USA |
 |
Dyadic International
DYAI
|
31.5 M | $ 0.41 | 3.72 % | $ 14.8 M | USA |
 |
Editas Medicine
EDIT
|
206 M | $ 2.69 | 0.17 % | $ 239 M | USA |
 |
Edesa Biotech
EDSA
|
11.3 M | $ 3.97 | 1.46 % | $ 22.5 M | USA |